Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
Mehrnoosh Pauls, Stephen Chia, Nathalie LeVasseur
Abstract
Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.
Topics & Concepts
MedicineTriple-negative breast cancerBreast cancerMetastatic breast cancerImmunotherapyOncologyTriple negativeCancerDiseaseInternal medicineAdvanced Breast Cancer TherapiesCancer Treatment and PharmacologyPARP inhibition in cancer therapy